Glucagon‐like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta‐analysis
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: The aim of the present study was to compare the reported efficacy and safety of glucagon‐like peptide‐l receptor agonist (GLP‐1RA) and insulin glargine (IGlar) for poorly controlled type 2 diabetes. Methods: Medline, EMBASE, C ochrane L ibrary, and clinicaltrials.gov were carried out. References and cited papers of relevant articles were also checked. Results: Seven trials met the inclusion criteria. GLP‐1RA showed equivalent or superior efficacy to IGlar for reducing hemoglobin A 1c (HbA1c), with a greater proportion of patients achieving HbAlc<7%. GLP‐1RA also favored decreased body weight, total cholesterol (TC), low‐density lipoprotein (LDL), and systolic blood pressure (SBP). Serious adverse events were uncommon and not significantly different. More patients taking GLP‐1RA experienced gastrointestinal complications: nausea, diarrhea, and vomiting. Severe hypoglycemia events were rare, and minor hypoglycemia was less common for GLP‐1RA. Conclusions: GLP‐1RA showed greater efficacy compared to IGlar for type 2 diabetes, and it may also prove beneficial for other diabetes‐associated characteristics, including obesity, hypertension, and hyperlipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · cited 1×
“Five of the eligible studies compared IGlar to exenatide and two compared to liraglutide.(19,23) In the systematic review and meta-analyses, 1587 patients randomized to IGlar and 1606 patients randomized to exenatide or liraglutide.”
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · cited 1×
“GLP-1 lowers glucagon secretion in type 2 diabetes in a glucose-dependent manner, thus preventing interference in the normal glucagon counter regulatory response to hypoglycemia.(25) In our meta-analysis, GLP1RA showed evidence of decreasing the incidence of minor hypoglycemia compared to IGlar.”
BackgroundDiamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Barnett, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2593 · Cited by 79
Garg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38
Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives
Stephens, J., & Edavalath, M. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s6358 · Cited by 17 · cited 1×
“Exenatide has been approved by the Food and Drug Administration for use as monotherapy along with lifestyle changes in type 2 diabetes patients since November 2009,(9) and liraglutide has been licensed for the treatment of type 2 diabetes in conjunction with diet and exercise since January 2010.(10) Both IGlar and GLP…”
Method
Cited by
Lingvay, I., Manghi, F. P., García-Hernández, P., Norwood, P., Lehmann, L., Tarp-Johansen, M. J., Buse, J. B., & for the DUAL V Investigators (2016) · JAMA · doi:10.1001/jama.2016.1252 · Cited by 220
Abd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12804 · Cited by 155
Singh, S., Wright, E. E., Kwan, A. Y. M., Thompson, J. C., Syed, I. A., Korol, E. E., Waser, N. A., Yu, M. B., & Juneja, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12805 · Cited by 101
Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24
Wang, Y., Wang, J., Gong, Q., Wu, H., Yang, S., He, J., Hu, X., & Huang, T. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0384 · Cited by 18
Metadata
- Authors
- Liu, F., Dong, J., Yang, Q., Xue, X., Ren, Z., Gan, Y., & Liao, L.
- Venue
- Journal of Diabetes
- Publisher
- Wiley
- Published
- 2014-09-10
- Volume
- 7
- Issue
- 3
- Pages
- 322-328
- ISSN
- 1753-0393 (ISSN-L)
- 1753-0407
- OpenAlex
- W2158530272
- Cited by
- 20
- References
- 10
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon‐like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta‐analysis. https://app.cochat.ai/papers/10.1111/1753-0407.12200
- The paper
- Liu, F., Dong, J., Yang, Q., Xue, X., Ren, Z., Gan, Y., & Liao, L. (2015). Glucagon‐like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta‐analysis. Journal of Diabetes. https://doi.org/10.1111/1753-0407.12200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.